JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2)
William Virgil Brown1, Yehuda Handelsman2, Seth S Martin3
1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Insights
Understanding cholesterol and triglycerides is key for metabolic and vascular disease risk. Advanced lipoprotein measures help physicians assess risk and guide therapy more effectively.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Lipidology
Background:
- Cholesterol and triglycerides are crucial indicators of metabolic disorders and vascular disease risk.
- Lipoproteins, the carriers of these lipids, have been a focus of study for over 50 years.
- Ongoing research continues to elucidate lipoprotein metabolism and its link to arteriosclerosis.
Purpose of the Study:
- To discuss the current importance of lipoprotein management in clinical practice.
- To highlight the evolving role of clinical laboratories in assessing lipoprotein-related risk.
- To explore future directions in lipoprotein measurement based on scientific advancements.
Main Methods:
- Roundtable discussion with physicians specializing in lipoprotein management.
- Review of current scientific literature on lipoprotein metabolism and arteriosclerosis.
- Analysis of clinical laboratory advancements in lipoprotein assessment.
Main Results:
- Physicians emphasize lipoprotein management as central to their practice.
- Advanced lipoprotein measures offer more focused risk assessment and targeted therapy.
- Scientific studies are driving changes in lipoprotein measurement and clinical application.
Conclusions:
- Lipoprotein management is critical for patients with metabolic disorders and at risk of vascular disease.
- Evolving scientific understanding necessitates advanced lipoprotein measures for effective patient care.
- Future research will likely lead to further refinements in assessing and managing lipoprotein-related risks.
Abstract:
The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.
More Related Videos
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...